Eco Animal Health Group PLC Chief Executive Officer Appointment (7382Y)
18 Enero 2022 - 01:00AM
UK Regulatory
TIDMEAH
RNS Number : 7382Y
Eco Animal Health Group PLC
18 January 2022
18 January 2022
ECO Animal Health Group plc
("ECO" or the "Company") (AIM: EAH)
Chief Executive Officer Appointment
ECO Animal Health Group plc, a leader in the development,
registration and marketing of pharmaceutical products for the
global animal health market, is pleased to announce that the Board
of the Company has approved David Hallas's appointment as Chief
Executive Officer and a member of the Board with effect from the 1
April 2022. This follows the announcement on the 26 July 2021
regarding Marc Loomes' intention to retire from ECO during
2022.
David Hallas has over 30 years of experience in the animal
health industry and is a qualified veterinarian. He is currently
managing director of Sure Petcare, a wholly owned subsidiary of
Merck Inc. providing digital based solutions to the companion
animal sector with sales of over US$170m. Prior to this role, he
was Associate Vice President of MSD Animal Health with full P&L
responsibility for mid Europe which comprised a group of 7 European
countries with a combined revenue of over US$450m; he has also held
senior global, regional and business unit management roles in other
animal health businesses within Merck, Schering Plough and Pfizer
(now Zoetis) and lived and worked overseas including in the USA.
David has substantial experience managing profitable growth through
the introduction of new products, including vaccines, and
successful merger and acquisition integrations.
Marc Loomes will resign from the Board of ECO on 1 April 2022
and has agreed to support David and the Company in an advisory role
for a period of time to ensure a full and thorough handover is
effected.
Andrew Jones, Chairman of ECO said:
"We are delighted that David has agreed to join ECO as CEO. He
has considerable experience in all our major markets and product
areas, and an excellent track record of managing and delivering
profitable growth both in large and smaller businesses. We look
forward to working with him to build shareholder value in the next
exciting phase of ECO's development. The Board also sincerely
thanks Marc for his invaluable contribution to the growth and
success of ECO over the last 17 years."
Additional Information on the Board Appointment :
The following additional information is provided with regards to
the appointment of David Charles Hallas aged 57, in accordance with
AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies:
Current directorships/partnerships:
Sureflap Limited
Sureflap LLC
Cambridge Resonant Technologies Ltd.
Directorships/partnerships within the last five years:
None
David Hallas does not currently hold any shares in the
Company.
There are no further disclosures required to be made in respect
of the appointment under AIM Rule 17 and Schedule 2(g) of the AIM
Rules for Companies.
Contacts:
ECO Animal Health Group plc
Marc Loomes (CEO)
Christopher Wilks (CFO) 020 8447 8899
IFC Advisory
Graham Herring
Zach Cohen 020 3934 6630
Singer Capital Markets (Nominated Adviser
& Joint Broker)
Mark Taylor
George Tzimas 020 7496 3000
Peel Hunt LLP (Joint Broker)
James Steel
Dr Christopher Golden 020 7418 8900
Investec (Joint Broker)
Gary Clarence
Alex Penney
Carlo Spingardi 020 7597 5970
Equity Developments
Hannah Crowe
Matt Evans 020 7065 2692
About ECO Animal Health
ECO Animal Health Group plc ("ECO" or "the Group") researches,
develops and commercialises products for livestock. Our business
strategy is to generate shareholder value by achieving the maximum
sales potential from the existing product portfolio whilst
investing in Research and Development ("R&D") for new products,
particularly vaccines, and seeking to in-license new products.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKDLFFLFLEBBL
(END) Dow Jones Newswires
January 18, 2022 02:00 ET (07:00 GMT)
Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Eco Animal Health (LSE:EAH)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024